The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

June 05, 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

June 04, 2023

Kanwal P. S. Raghav, MBBS, MD, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.

June 04, 2023

The 5.4-mg/kg dose of trastuzumab deruxtecan elicited numerically higher activity in patients with HER2-positive, metastatic colorectal cancer compared with the 6.4-mg/kg dose.

June 03, 2023

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.

June 02, 2023

Guillermo Garcia-Manero, MD, discusses key efficacy and safety findings from the phase 3 COMMANDS trial (NCT03682536) of luspatercept-aamt (Reblozyl) vs epoetin alfa in patients with lower-risk myelodysplastic syndrome.

June 02, 2023

Samer A. Srour, MB ChB, MS, discusses planned next steps and future avenues of investigation for the novel CD70-targeted agent ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

May 29, 2023

Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients. 

May 26, 2023

The combination of durvalumab and platinum-based chemotherapy, followed by maintenance therapy with either durvalumab plus olaparib or durvalumab alone, elicited a statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed, advanced or recurrent endometrial cancer.

May 25, 2023

Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

May 25, 2023

Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.

May 23, 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

May 22, 2023

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 19, 2023

John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.

May 19, 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

May 10, 2023

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.

May 04, 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

May 01, 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses molecular determinants of KRAS G12C inhibitor efficacy in advanced non–small cell lung cancer.

April 28, 2023

Elshad Hasanov, MD, PhD, discusses actionable immune-resistance targets in patients with renal cell carcinoma with brain metastases.

April 27, 2023

Michael Andreeff, MD, PhD, discusses the potential benefits of E-selectin inhibition in the AML tumor microenvironment, data that have contributed to the further development of uproleselan in this population, and additional AML targets under investigation that may broaden the treatment landscape.